{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T07:49:17Z","timestamp":1792309757187,"version":"4.4.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T00:00:00Z","timestamp":1513382400000},"content-version":"am","delay-in-days":380,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HDTRA1-13-1-0044"],"award-info":[{"award-number":["HDTRA1-13-1-0044"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R21EB020781-01"],"award-info":[{"award-number":["1R21EB020781-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.jconrel.2016.06.040","type":"journal-article","created":{"date-parts":[[2016,6,28]],"date-time":"2016-06-28T13:16:10Z","timestamp":1467119770000},"page":"184-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":649,"special_numbering":"PB","title":["Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation"],"prefix":"10.1016","volume":"244","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5409-7480","authenticated-orcid":false,"given":"Peng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2016.06.040_bb0005","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrd4363","article-title":"Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies","volume":"13","author":"Mitragotri","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0010","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S1359-6446(03)02953-2","article-title":"Minimizing the immunogenicity of protein therapeutics","volume":"9","author":"Chirino","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0015","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0020","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nbt1303","article-title":"A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs","volume":"25","author":"Shankar","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0025","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0030","doi-asserted-by":"crossref","first-page":"10272","DOI":"10.1021\/jp014345v","article-title":"Hydration study of PEG\/water mixtures by quasi elastic light scattering, acoustic and rheological measurements","volume":"106","author":"Branca","year":"2002","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0035","doi-asserted-by":"crossref","first-page":"8931","DOI":"10.1021\/la036345n","article-title":"Molecular simulation study of water interactions with oligo (ethylene glycol)-terminated alkanethiol self-assembled monolayers","volume":"20","author":"Zheng","year":"2004","journal-title":"Langmuir"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0040","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1529\/biophysj.105.059428","article-title":"Strong repulsive forces between protein and oligo (ethylene glycol) self-assembled monolayers: a molecular simulation study","volume":"89","author":"Zheng","year":"2005","journal-title":"Biophys. J."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0045","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1016\/S0021-9258(17)40291-2","article-title":"Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol","volume":"252","author":"Abuchowski","year":"1977","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0050","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jconrel.2014.06.046","article-title":"PEG - a versatile conjugating ligand for drugs and drug delivery systems","volume":"192","author":"Kolate","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0055","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1039\/c1py00034a","article-title":"FDA-approved poly(ethylene glycol)\u2013protein conjugate drugs","volume":"2","author":"Alconcel","year":"2011","journal-title":"Polym. Chem."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0060","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/biot.200900218","article-title":"PEGylation of therapeutic proteins","volume":"5","author":"Jevsevar","year":"2010","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0065","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/S0021-9258(17)40292-4","article-title":"Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase","volume":"252","author":"Abuchowski","year":"1977","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0070","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000233309","article-title":"Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins","volume":"70","author":"Richter","year":"1983","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0075","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","article-title":"Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents","volume":"9","author":"Garay","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0080","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0085","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0090","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(13)61841-3","article-title":"Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial","volume":"384","author":"Longo","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0095","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2006.01.005","article-title":"Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes","volume":"112","author":"Ishida","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0168-3659(02)00462-5","article-title":"Accelerated clearance of PEGylated liposomes in rats after repeated injections","volume":"88","author":"Ishida","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0110","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jconrel.2012.11.016","article-title":"Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon","volume":"165","author":"Shiraishi","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0115","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2007.11.005","article-title":"Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes","volume":"354","author":"Ishida","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0120","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ymthe.2005.09.014","article-title":"Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes","volume":"13","author":"Judge","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0125","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.imbio.2015.06.005","article-title":"Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells","volume":"220","author":"Shimizu","year":"2015","journal-title":"Immunobiology"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0130","first-page":"3533","article-title":"Accelerated blood clearance phenomenon upon cross-administration of PEGylated nanocarriers in beagle dogs","volume":"10","author":"Wang","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0135","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jconrel.2007.05.015","article-title":"PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner","volume":"122","author":"Ishida","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0140","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","article-title":"The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage","volume":"172","author":"Abu Lila","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0145","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1021\/ac1009832","article-title":"Immunoaffinity purification using anti-PEG antibody followed by two-dimensional liquid chromatography\/tandem mass spectrometry for the quantification of a PEGylated therapeutic peptide in human plasma","volume":"82","author":"Xu","year":"2010","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0150","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1021\/bc100067t","article-title":"Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies","volume":"21","author":"Su","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0155","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1089\/hyb.2007.006","article-title":"Generation and characterization of a monoclonal IgG antibody to polyethylene glycol","volume":"26","author":"Wunderlich","year":"2007","journal-title":"Hybridoma (Larchmt)"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0160","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1535-7163.MCT-15-0151","article-title":"Selective delivery of PEGylated compounds to tumor cells by anti-PEG hybrid antibodies","volume":"14","author":"Tung","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0165","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s11095-013-1067-7","article-title":"The immunogenicity of polyethylene glycol: facts and fiction","volume":"30","author":"Schellekens","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0170","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/wnan.1339","article-title":"Anti-PEG immunity: emergence, characteristics, and unaddressed questions","volume":"7","author":"Yang","year":"2015","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0175","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.addr.2007.06.011","article-title":"PEG-uricase in the management of treatment-resistant gout and hyperuricemia","volume":"60","author":"Sherman","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0180","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0185","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0190","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","article-title":"Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout","volume":"56","author":"Sundy","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0195","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/art.23810","article-title":"I. Pegloticase Phase 2 Study, Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study","volume":"58","author":"Sundy","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0200","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1021\/acs.molpharmaceut.5b00144","article-title":"Anti-PEG IgM is a major contributor to the accelerated blood clearance of polyethylene glycol-conjugated protein","volume":"12","author":"Mima","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0205","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00003088-200544040-00003","article-title":"Pharmacokinetic\/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future","volume":"44","author":"Avramis","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0210","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1365-2141.2000.02187.x","article-title":"Pegylated asparaginase (Oncaspar\u2122) in children with ALL: drug monitoring in reinduction according to the ALL\/NHL-BFM 95 protocols","volume":"110","author":"Muller","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0215","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pbc.25319","article-title":"PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol","volume":"62","author":"Henriksen","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0220","doi-asserted-by":"crossref","unstructured":"L.M. Vrooman, Kirov, Z.E. II, Dreyer, M., Kelly, N., Hijiya, P., Brown, R.A., Drachtman, Y.H., Messinger, A.K., Ritchey, G.A., Hale, K., Maloney, Y., Lu, P.V., Plourde, L.B., Silverman, activity and toxicity of intravenous Erwinia asparaginase following allergy to E. coli-derived asparaginase in children and adolescents with acute lymphoblastic leukemia, Pediatr. Blood Cancer, 63 (2016) 228\u2013233.","DOI":"10.1002\/pbc.25757"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0225","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1586\/17474086.2016.1142370","article-title":"Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase","volume":"9","author":"Figueiredo","year":"2016","journal-title":"Expert. Rev. Hematol."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0230","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.jaci.2015.10.034","article-title":"Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer","volume":"137","author":"Ganson","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0235","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1398-9995.2005.00783.x","article-title":"Anaphylaxis to macrogol 4000 after a parenteral corticoid injection","volume":"60","author":"Dewachter","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0240","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000233512","article-title":"Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors","volume":"74","author":"Richter","year":"1984","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0245","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/S0168-8278(10)60309-1","article-title":"307 high prevalence of pre-existing antibodies against polyethylene glycol (Peg) in hepatitis C (Hcv) patients which is not associated with impaired response to Peg-interferon","volume":"52","author":"Tillmann","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0250","first-page":"556A","article-title":"Occurrence of an antibody to poly(ethylene glycol) in normal donors","volume":"102","author":"Armstrong","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0255","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1177\/0961203315574558","article-title":"First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus","volume":"24","author":"Tocoian","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0260","doi-asserted-by":"crossref","DOI":"10.1177\/1756285616633967","article-title":"Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial","author":"White","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0265","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.molimm.2012.05.011","article-title":"Structural and immunologic characterization of bovine, horse, and rabbit serum albumins","volume":"52","author":"Majorek","year":"2012","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0270","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1021\/bc200551b","article-title":"Role of the methoxy group in immune responses to mPEG-protein conjugates","volume":"23","author":"Sherman","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0275","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.molimm.2013.07.014","article-title":"Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins","volume":"57","author":"Saifer","year":"2014","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0280","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.drudis.2014.08.015","article-title":"Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics","volume":"19","author":"Verhoef","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0285","first-page":"37","article-title":"Repeated injections of PEG-PE liposomes generate anti-PEG antibodies","volume":"10","author":"Sroda","year":"2005","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0290","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.vascn.2011.07.003","article-title":"A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers","volume":"64","author":"Liu","year":"2011","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0295","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1208\/s12248-015-9799-4","article-title":"Development of a generic anti-PEG antibody assay using BioScale's acoustic membrane MicroParticle technology","volume":"17","author":"Dong","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0300","doi-asserted-by":"crossref","first-page":"12046","DOI":"10.1073\/pnas.1512465112","article-title":"Zwitterionic gel encapsulation promotes protein stability, enhances pharmacokinetics, and reduces immunogenicity","volume":"112","author":"Zhang","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0305","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1021\/bm800407r","article-title":"Nonfouling behavior of polycarboxybetaine-grafted surfaces: structural and environmental effects","volume":"9","author":"Zhang","year":"2008","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0310","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0165-2478(81)90024-9","article-title":"A conjugate between a purified timothy allergen and poly(N-vinylpyrrolidone) suppresses the specific IgE response in mice","volume":"2","author":"Smorodinsky","year":"1981","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0315","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jconrel.2012.02.025","article-title":"Selective conjugation of poly(2-ethyl 2-oxazoline) to granulocyte colony stimulating factor","volume":"159","author":"Mero","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0320","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1749-6632.1987.tb45752.x","article-title":"New acrylic polymers for surface modification of enzymes of therapeutic interest and for enzyme immobilization","volume":"501","author":"Veronese","year":"1987","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0325","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/088391159300800202","article-title":"Evaluation of poly(vinyl alcohol) for protein tailoring: Improvements in pharmacokinetic properties of superoxide dismutase","volume":"8","author":"Kojima","year":"1993","journal-title":"J. Bioact. Compat. Polym."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0330","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1016\/j.bmcl.2015.09.055","article-title":"Dendronylation: residue-specific chemoselective attachment of oligoglycerol dendrimers on proteins with noncanonical amino acids","volume":"25","author":"Ma","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0335","doi-asserted-by":"crossref","unstructured":"A. Lewis, Y. Tang, S. Brocchini, J.W. Choi, A. Godwin, Poly(2-methacryloyloxyethyl phosphorylcholine) for protein conjugation, Bioconjug. Chem., 19 (2008) 2144\u20132155.","DOI":"10.1021\/bc800242t"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0340","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nchem.1213","article-title":"Poly(zwitterionic)protein conjugates offer increased stability without sacrificing binding affinity or bioactivity","volume":"4","author":"Keefe","year":"2012","journal-title":"Nat. Chem."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0345","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jconrel.2008.07.023","article-title":"Dextrin-rhEGF conjugates as bioresponsive nanomedicines for wound repair","volume":"130","author":"Hardwicke","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0350","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/nbt.1588","article-title":"A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner","volume":"27","author":"Schellenberger","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0355","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1021\/acs.biomac.5b01031","article-title":"EKylation: addition of an alternating-charge peptide stabilizes proteins","volume":"16","author":"Liu","year":"2015","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0360","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/protein\/gzt023","article-title":"PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins","volume":"26","author":"Schlapschy","year":"2013","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0365","doi-asserted-by":"crossref","first-page":"14323","DOI":"10.1021\/ja504390x","article-title":"Therapeutic protein-polymer conjugates: advancing beyond PEGylation","volume":"136","author":"Pelegri-O'Day","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0370","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cbpa.2015.08.009","article-title":"Protein-polymer conjugation-moving beyond PEGylation","volume":"28","author":"Qi","year":"2015","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0375","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4049\/jimmunol.77.2.105","article-title":"The antigenicity of polyvinyl pyrrolidone","volume":"77","author":"Maurer","year":"1956","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0380","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4049\/jimmunol.79.1.84","article-title":"The antigenicity of polyvinyl pyrrolidone. II","volume":"79","author":"Maurer","year":"1957","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0385","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.4049\/jimmunol.102.5.1309","article-title":"Induction of immunity and immunologic paralysis in mice against polyvinyl pyrrolidone","volume":"102","author":"Andersson","year":"1969","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0390","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1021\/bc000119x","article-title":"Immunological properties of uricase conjugated to neutral soluble polymers","volume":"12","author":"Caliceti","year":"2001","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0395","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/adma.200901407","article-title":"Ultralow-fouling, functionalizable, and hydrolyzable zwitterionic materials and their derivatives for biological applications","volume":"22","author":"Jiang","year":"2010","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0400","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nmat1233","article-title":"Surface grafting of artificial joints with a biocompatible polymer for preventing periprosthetic osteolysis","volume":"3","author":"Moro","year":"2004","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0405","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/adma.201404059","article-title":"Molecular understanding and design of zwitterionic materials","volume":"27","author":"Shao","year":"2015","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0410","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1002\/smll.201303540","article-title":"Zwitterionic-coated \u201cstealth\u201d nanoparticles for biomedical applications: recent advances in countering biomolecular corona formation and uptake by the mononuclear phagocyte system","volume":"10","author":"Pombo Garcia","year":"2014","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2016.05.006","article-title":"Chemical conjugation of zwitterionic polymers protects immunogenic enzyme and preserves bioactivity without polymer-specific antibody response","author":"Liu","year":"2016","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0420","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jconrel.2016.04.008","article-title":"Butyrylcholinesterase nanocapsule as a long circulating bioscavenger with reduced immune response","volume":"230","author":"Zhang","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0425","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1007\/s12274-016-0991-3","article-title":"Phosphorylcholine polymer nanocapsules prolong the circulation time and reduce the immunogenicity of therapeutic proteins","volume":"9","author":"Liang","year":"2016","journal-title":"Nano Res."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010175","article-title":"Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose","volume":"5","author":"Geething","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050630","article-title":"GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model","volume":"7","author":"Alters","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0440","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1002\/jps.23229","article-title":"A novel long-acting human growth hormone fusion protein (VRS-317): enhanced in vivo potency and half-life","volume":"101","author":"Cleland","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0445","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.113.128108","article-title":"XTEN-annexin A5: XTEN allows complete expression of long-circulating protein-based imaging probes as recombinant alternative to PEGylation","volume":"55","author":"Haeckel","year":"2014","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0450","doi-asserted-by":"crossref","first-page":"29014","DOI":"10.1074\/jbc.M114.602474","article-title":"Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis","volume":"289","author":"Harari","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0455","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1021\/mp5007147","article-title":"PASylation of murine leptin leads to extended plasma half-life and enhanced in vivo efficacy","volume":"12","author":"Morath","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0460","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1039\/c2sc21135a","article-title":"Decoding nonspecific interactions from nature","volume":"3","author":"White","year":"2012","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0465","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1016\/j.biomaterials.2009.07.001","article-title":"Ultra-low fouling peptide surfaces derived from natural amino acids","volume":"30","author":"Chen","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2016.06.040_bb0470","doi-asserted-by":"crossref","first-page":"6000","DOI":"10.1021\/ja3006868","article-title":"Sequence, structure, and function of peptide self-assembled monolayers","volume":"134","author":"Nowinski","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2016.06.040_bb0475","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1021\/la404980g","article-title":"Biologically inspired stealth peptide-capped gold nanoparticles","volume":"30","author":"Nowinski","year":"2014","journal-title":"Langmuir"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916304175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916304175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:32:06Z","timestamp":1759159926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365916304175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":95,"alternative-id":["S0168365916304175"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.06.040","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.06.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}